Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

Imaging technique allows study of early stage Alzheimer’s disease

Scientists used optical photothermal spectroscopy (O-PTIR) to image murine neurons affected by early stage Alzheimer’s disease, providing insight into the progression of the disease.

amyloid plaque forming on a neuron

Neuron (purple) with beta-amyloid plaque forming (yellow).

In order to study the early stages of Alzheimer’s disease (AD), researchers have used a new imaging method, called optical photothermal spectroscopy (O-PTIR), to visualise the protein structures within live nerve cells.

According to researchers, one of the major roadblocks to effective AD therapies is that they have been unable to study the early protein structural changes that occur before visible plaques appear. Essentially, they have been unable to answer: what happens in the nerve cells before amyloid plaques appear and why do nerve cells die?

“This is a question that researchers have long struggled to find answers to. We have not had enough imaging techniques to study the structural changes in nerve cells. This is required to detect very early changes, and therefore potentially understand the triggers,” said researcher Oxana Klementieva, group leader for medical microscopy at Lund University, Sweden.

 

Access your FREE copy

 


Biomarkers aren’t just supporting drug discovery – they’re driving it

FREE market report

From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.

What you’ll unlock:

  • How biomarkers are guiding dose selection and early efficacy decisions in complex trials
  • Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
  • What makes lab data regulatory-ready and why alignment matters from day one

Explore how biomarkers are shaping early drug development

Access the full report – it’s free!

 

In a study published in Advanced Science, Klementieva and her team used O-PTIR to study protein structures within nerve cells affected by early-stage AD in mice, before cell death occurred. The process did not require the use of chemical processing of nerve cells, unlike other imaging techniques, which can affect the structure of neurons.

“We saw that the structure of the protein changes in different ways depending on where in the nerve cell it is. So far, there have been no methods that can produce these types of images, giving us insight into what the first molecular changes in neurons actually look like in Alzheimer’s disease,” explained Klementieva.

In previous research projects, Klementieva and colleagues demonstrated that early structural changes of beta-amyloid happen before the AD hallmark amyloid plaques appear. They now intend to investigate where in the cell these structural changes occur in the hopes it may explain the mechanisms underlying AD.

“If it depends on several different mechanisms, something I believe to be the case, we would need different types of treatments,” said Klementieva.

The team believe the O-PTIR technology could also be leveraged in studies of related diseases like Parkinson’s, Lewy Body dementia and frontal lobe dementia.